A magnified coronavirus germ is displayed on a desktop computer monitor during coronavirus patient sample detection tests in the virology research labs (Representational Image) | Photographer: Geert Vanden Wijngaert | Bloomberg
Representational Image | Photographer: Geert Vanden Wijngaert | Bloomberg
Text Size:

An experimental coronavirus vaccine developed by Translate Bio Inc. and French drug giant Sanofi elicited high levels of protective neutralizing antibodies in early-stage animal studies, clearing the way for a clinical trial to start later this year.

Two doses of the candidate induced neutralizing antibodies “significantly higher” than those observed in Covid-19 patients as well as a response in infection-fighting T-cells in non-human primates, the companies said in a statement.

The candidate is a so-called messenger RNA vaccine, which prompts the body to make a key protein from the virus, sparking an immune response. It’s based on technology similar to that used by one of the fastest-moving vaccine developers, Moderna Inc.

Sanofi is developing another coronavirus vaccine in collaboration with GlaxoSmithKline Plc. That shot is already in a clinical trial, and first results are expected in early December to support the start of a broader phase 3 study before the end of the year, Sanofi said.

In an August filing, Translate Bio had cited Sanofi slides and disclosed that the mRNA vaccine had induced antibody protection that was “comparable to the upper range of those observed in infected humans.”-Bloomberg


Also read: National Medical Commission proposes new rules, likely to abolish 5-acre land requirement


 

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

India needs free, fair, non-hyphenated and questioning journalism even more as it faces multiple crises.

But the news media is in a crisis of its own. There have been brutal layoffs and pay-cuts. The best of journalism is shrinking, yielding to crude prime-time spectacle.

ThePrint has the finest young reporters, columnists and editors working for it. Sustaining journalism of this quality needs smart and thinking people like you to pay for it. Whether you live in India or overseas, you can do it here.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here